TransCode Therapeutics, Inc. (RNAZ) Dividend History

Company News

• US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert

  U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.

  Benzinga

  Featured Companies: BON CMI F FFAI HSIC PLRZ QQQ SPY TSN
• Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga

  Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.

  Benzinga
• Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus

  Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

  Zacks Investment Research

  Featured Companies: AMGN CL DCTH GS KO LMFA MTD MU OUST
• Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

  Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

  GlobeNewswire Inc.
• TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

  TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

  GlobeNewswire Inc.